Exploring the interactions between the anti-tuberculosis agent, pyrazinamide/pyrazonoic acid, and lipid model membrane systems

被引：0
|
作者：
Hough, John Peter [1 ]
Groninger, Allison [1 ]
Peters, Benjamin [2 ]
Fontes, Fabio Levi [3 ,4 ]
Crick, Dean [3 ,4 ]
Crans, Debbie [2 ,3 ]
机构：
[1] Colorado State Univ, Dept Biochem, Ft Collins, CO 80523 USA
[2] Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA
[3] Colorado State Univ, Cell & Mol Biol Program, Ft Collins, CO 80523 USA
[4] Colorado State Univ, Mycobacteria Res Labs, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2017年 / 253卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
203
引用
收藏
页数：1
相关论文
共 40 条
  • [1] Novel lead generation of an anti-tuberculosis agent active against non-replicating mycobacteria: exploring hybridization of pyrazinamide with multiple fragments
    Shankar D. Markad
    Parvinder Kaur
    B. K. Kishore Reddy
    Murugan Chinnapattu
    Anandkumar Raichurkar
    Radha Nandishaiah
    Manoranjan Panda
    Pravin S. Iyer
    Medicinal Chemistry Research, 2015, 24 : 2986 - 2992
  • [2] Novel lead generation of an anti-tuberculosis agent active against non-replicating mycobacteria: exploring hybridization of pyrazinamide with multiple fragments
    Markad, Shankar D.
    Kaur, Parvinder
    Reddy, B. K. Kishore
    Chinnapattu, Murugan
    Raichurkar, Anandkumar
    Nandishaiah, Radha
    Panda, Manoranjan
    Iyer, Pravin S.
    MEDICINAL CHEMISTRY RESEARCH, 2015, 24 (07) : 2986 - 2992
  • [3] Pyrazinoic acid, the active form of the anti-tuberculosis drug pyrazinamide, and aromatic carboxylic acid analogs are protonophores
    Fontes, Fabio L.
    Rooker, Steven A.
    Lynn-Barbe, Jamie K.
    Lyons, Michael A.
    Crans, Debbie C.
    Crick, Dean C.
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2024, 11
  • [4] Development of a novel anti-tuberculosis nanodelivery formulation using magnesium layered hydroxide as the nanocarrier and pyrazinamide as a model drug
    Bullo Saifullah
    Palanisamy Arulselvan
    Sharida Fakurazi
    Thomas J. Webster
    Naeemullah Bullo
    Mohd Zobir Hussein
    Mohamed E. El Zowalaty
    Scientific Reports, 12
  • [5] Development of a novel anti-tuberculosis nanodelivery formulation using magnesium layered hydroxide as the nanocarrier and pyrazinamide as a model drug
    Saifullah, Bullo
    Arulselvan, Palanisamy
    Fakurazi, Sharida
    Webster, Thomas J.
    Bullo, Naeemullah
    Hussein, Mohd Zobir
    El Zowalaty, Mohamed E.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [6] Terahertz and Raman Spectroscopic Investigation of Anti-tuberculosis Drug-Drug Cocrystallization Involving 4-aminosalicylic Acid and Pyrazinamide
    Zhang, Ziming
    Fang, Jiyuan
    Bo, Yanhua
    Xue, Jiadan
    Liu, Jianjun
    Hong, Zhi
    Du, Yong
    JOURNAL OF MOLECULAR STRUCTURE, 2021, 1227
  • [7] Pharmacokinetic interaction between the investigational anti-tuberculosis agent TMC207 and rifampicin or rifapentin
    Everitt, D.
    Winter, H.
    Egizi, E.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 43 - 43
  • [8] Application of ImmunoScore Model for the Differentiation between Active Tuberculosis and Latent Tuberculosis Infection as Well as Monitoring Anti-tuberculosis Therapy
    Zhou, Yu
    Du, Juan
    Hou, Hong-Yan
    Lu, Yan-Fang
    Yu, Jing
    Mao, Li-Yan
    Wang, Feng
    Sun, Zi-Yong
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2017, 7
  • [9] MONOPOLAR-BIPOLAR LIPID INTERACTIONS IN MODEL MEMBRANE SYSTEMS
    MIRGHANI, Z
    BERTOIA, D
    GLIOZZI, A
    DEROSA, M
    GAMBACORTA, A
    CHEMISTRY AND PHYSICS OF LIPIDS, 1990, 55 (02) : 85 - 96
  • [10] Anti-tuberculosis activity and drug interaction with nevirapine of inhalable lipid microspheres containing rifampicin in murine model
    Disratthakit, Areeya
    Doi, Norio
    Takenaga, Mitsuko
    Ohta, Yuki
    JOURNAL OF MICROENCAPSULATION, 2010, 27 (04) : 365 - 371
1234